With an analyst consensus upside of 79.4%, Alumis Inc. (NASDAQ:ALMS) ranks among the under-the-radar stocks with massive upside for 2026. Alumis Inc. (NASDAQ:ALMS) drew three analyst price target ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
3mon
Alumis Inc.
View Alumis Inc. ALMS stock quote prices, financial information, real-time forecasts, and company news from CNN.
ALMS surged 95.3% after envudeucitinib met all endpoints in two phase III plaque psoriasis studies. Envudeucitinib delivered strong PASI and sPGA skin clearance results in moderate-to-severe plaque ...
Hosted on MSN
Chardan highlights Alumis’s (ALMS) potential after envudeucitinib hits all phase 3 endpoints in psoriasis trials
Alumis Inc. (NASDAQ:ALMS) is one of the new stocks on the rise. On January 21, Chardan initiated coverage of Alumis with a Buy rating and a $37 price target driven by the significant potential of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results